Synthesis and immunological activity of water-soluble Thalidomide prodrugs

A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2001-05, Vol.9 (5), p.1279-1291
Hauptverfasser: Hess, Sonja, Akermann, Michaela A., Wnendt, Stephan, Zwingenberger, Kai, Eger, Kurt
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1291
container_issue 5
container_start_page 1279
container_title Bioorganic & medicinal chemistry
container_volume 9
creator Hess, Sonja
Akermann, Michaela A.
Wnendt, Stephan
Zwingenberger, Kai
Eger, Kurt
description A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012 mg/mL). The amorphous hydrochlorides of the N-methylalanine ester 8, valine ester 9, and glycylglycine ester 10, respectively, were the most soluble compounds showing solubility greater than 300 mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications. Graphic
doi_str_mv 10.1016/S0968-0896(00)00342-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70880694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089600003424</els_id><sourcerecordid>70880694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi0EKtttfwJVJCTUHgLjj03sE0KrfoCQOOz2bDn2GFwlMdgJ1f57suwKjpzmMM877-gh5ITCOQVaXaxAVbIEqarvAD8AuGClOCAzKipRcq7oIZm9Icfkc87_AIAJRT-RY0p5XVNZzcjNatMPD5hDLkzvitB1Yx_beB-saQtjh_Achk0RffHfDJjKHNuxabFYP5g2uNgFh8Vjii6N9_kLOfKmzfh1P-fk76-f6-Wf8vbu9_Xy6ra0QsJQLqynzvrGMGmsZMY7xhdW1g6BI5MLgZaxmtXWs2nLlFG-bhpuRSO8apjic3K2uzsVP42YB92FbLFtTY9xzLoGKaFSYgIXO9CmmHNCrx9T6EzaaAp6K1G_StRbQxpAv0rU29y3fcHYdOjeU3trE3C6B0yePPlkehvyG6dUzSSfqMsdhZOM54BJZxuwt-hCQjtoF8MHj7wAt6KPcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70880694</pqid></control><display><type>article</type><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</creator><creatorcontrib>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</creatorcontrib><description>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012 mg/mL). The amorphous hydrochlorides of the N-methylalanine ester 8, valine ester 9, and glycylglycine ester 10, respectively, were the most soluble compounds showing solubility greater than 300 mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications. Graphic</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(00)00342-4</identifier><identifier>PMID: 11377186</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Binding Sites ; Biological and medical sciences ; Drug Stability ; Humans ; Hydrogen-Ion Concentration ; Hydrolysis ; Immunomodulators ; Interleukin-2 - antagonists &amp; inhibitors ; Interleukin-2 - biosynthesis ; Kinetics ; Male ; Medical sciences ; Mice ; Permeability ; Pharmacology. Drug treatments ; Shwartzman Phenomenon - metabolism ; Solubility ; Thalidomide - chemical synthesis ; Thalidomide - chemistry ; Thalidomide - pharmacology ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors ; Water - chemistry</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2001-05, Vol.9 (5), p.1279-1291</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0968-0896(00)00342-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=997283$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11377186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hess, Sonja</creatorcontrib><creatorcontrib>Akermann, Michaela A.</creatorcontrib><creatorcontrib>Wnendt, Stephan</creatorcontrib><creatorcontrib>Zwingenberger, Kai</creatorcontrib><creatorcontrib>Eger, Kurt</creatorcontrib><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012 mg/mL). The amorphous hydrochlorides of the N-methylalanine ester 8, valine ester 9, and glycylglycine ester 10, respectively, were the most soluble compounds showing solubility greater than 300 mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications. Graphic</description><subject>Animals</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Drug Stability</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hydrolysis</subject><subject>Immunomodulators</subject><subject>Interleukin-2 - antagonists &amp; inhibitors</subject><subject>Interleukin-2 - biosynthesis</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Permeability</subject><subject>Pharmacology. Drug treatments</subject><subject>Shwartzman Phenomenon - metabolism</subject><subject>Solubility</subject><subject>Thalidomide - chemical synthesis</subject><subject>Thalidomide - chemistry</subject><subject>Thalidomide - pharmacology</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Water - chemistry</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhi0EKtttfwJVJCTUHgLjj03sE0KrfoCQOOz2bDn2GFwlMdgJ1f57suwKjpzmMM877-gh5ITCOQVaXaxAVbIEqarvAD8AuGClOCAzKipRcq7oIZm9Icfkc87_AIAJRT-RY0p5XVNZzcjNatMPD5hDLkzvitB1Yx_beB-saQtjh_Achk0RffHfDJjKHNuxabFYP5g2uNgFh8Vjii6N9_kLOfKmzfh1P-fk76-f6-Wf8vbu9_Xy6ra0QsJQLqynzvrGMGmsZMY7xhdW1g6BI5MLgZaxmtXWs2nLlFG-bhpuRSO8apjic3K2uzsVP42YB92FbLFtTY9xzLoGKaFSYgIXO9CmmHNCrx9T6EzaaAp6K1G_StRbQxpAv0rU29y3fcHYdOjeU3trE3C6B0yePPlkehvyG6dUzSSfqMsdhZOM54BJZxuwt-hCQjtoF8MHj7wAt6KPcA</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>Hess, Sonja</creator><creator>Akermann, Michaela A.</creator><creator>Wnendt, Stephan</creator><creator>Zwingenberger, Kai</creator><creator>Eger, Kurt</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010501</creationdate><title>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</title><author>Hess, Sonja ; Akermann, Michaela A. ; Wnendt, Stephan ; Zwingenberger, Kai ; Eger, Kurt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-5cf1dcfba28ac82afd235c87de03e2854ec22727cf282a29a9f7bb3c4b4f9b293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Drug Stability</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hydrolysis</topic><topic>Immunomodulators</topic><topic>Interleukin-2 - antagonists &amp; inhibitors</topic><topic>Interleukin-2 - biosynthesis</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Permeability</topic><topic>Pharmacology. Drug treatments</topic><topic>Shwartzman Phenomenon - metabolism</topic><topic>Solubility</topic><topic>Thalidomide - chemical synthesis</topic><topic>Thalidomide - chemistry</topic><topic>Thalidomide - pharmacology</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Water - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hess, Sonja</creatorcontrib><creatorcontrib>Akermann, Michaela A.</creatorcontrib><creatorcontrib>Wnendt, Stephan</creatorcontrib><creatorcontrib>Zwingenberger, Kai</creatorcontrib><creatorcontrib>Eger, Kurt</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hess, Sonja</au><au>Akermann, Michaela A.</au><au>Wnendt, Stephan</au><au>Zwingenberger, Kai</au><au>Eger, Kurt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and immunological activity of water-soluble Thalidomide prodrugs</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2001-05-01</date><risdate>2001</risdate><volume>9</volume><issue>5</issue><spage>1279</spage><epage>1291</epage><pages>1279-1291</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012 mg/mL). The amorphous hydrochlorides of the N-methylalanine ester 8, valine ester 9, and glycylglycine ester 10, respectively, were the most soluble compounds showing solubility greater than 300 mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors k′. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-α and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-α release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications. Graphic</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11377186</pmid><doi>10.1016/S0968-0896(00)00342-4</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2001-05, Vol.9 (5), p.1279-1291
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_70880694
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Binding Sites
Biological and medical sciences
Drug Stability
Humans
Hydrogen-Ion Concentration
Hydrolysis
Immunomodulators
Interleukin-2 - antagonists & inhibitors
Interleukin-2 - biosynthesis
Kinetics
Male
Medical sciences
Mice
Permeability
Pharmacology. Drug treatments
Shwartzman Phenomenon - metabolism
Solubility
Thalidomide - chemical synthesis
Thalidomide - chemistry
Thalidomide - pharmacology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Water - chemistry
title Synthesis and immunological activity of water-soluble Thalidomide prodrugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20immunological%20activity%20of%20water-soluble%20Thalidomide%20prodrugs&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Hess,%20Sonja&rft.date=2001-05-01&rft.volume=9&rft.issue=5&rft.spage=1279&rft.epage=1291&rft.pages=1279-1291&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(00)00342-4&rft_dat=%3Cproquest_cross%3E70880694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70880694&rft_id=info:pmid/11377186&rft_els_id=S0968089600003424&rfr_iscdi=true